Reg. name: Vidaza
Class: Hypomethylating agent
The Summary of Product Characteristics for Vidaza® states that the antineoplastic effects of azacitidine are thought to be achieved through various mechanisms. These include a cytotoxic effect on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. In addition, inhibition of DNA, RNA, and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
- Vidaza® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/21508. [Accessed January 2017].
VIDAZA® is indicated for the treatment of adult patients who are not eligible for Haematopoietic Stem Cell Transplantation (HSCT) with Acute Myeloid leukemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification
Reg. name: Vyxeos®
CPX-351 is a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5 and it is designed to deliver synergistic drug ratios to leukemia cells.
- Gordon M.J. et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. Epub 2016 Dec 12;53:39-49. DOI: 10.1016/j.leukres.2016.12.002.
VYXEOS® is indicated for the treatment of adults with newly-diagnosed Therapy-related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)